ATS: Clinical Practice Guidelines on the Pharmacologic Management of COPD
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
Antiplatelet therapy may delay progression of COPD, decrease the risk for acute exacerbations, improve quality of life, and even reduce all-cause mortality.
The use of regular, low-dose, oral sustained-release morphine for 4 weeks in patients with COPD and moderate to very severe breathlessness has been shown to improve disease-specific health status.
In patients with COPD, interstitial lung abnormalities are significantly associated with moderate to severe acute disease exacerbations and with an accelerated decline in lung function.
Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD.
In patients with COPD, subclinical left ventricular systolic dysfunction is likely to be detected when measured by tissue Doppler imaging, even in patients without pulmonary hypertension.
Dysanapsis may be associated with a higher incidence of COPD in older adults.
In patients with COPD, treatment with single-inhaler fluticasone furoate/umeclidinium/vilanterol resulted in more health status improvements and greater lung function benefit compared with multiple-inhaler triple therapy.
An 8-week, feasible, novel lifestyle program was pilot-tested to evaluate its effectiveness in improving dyspnea in patients with chronic respiratory disease and obesity.
In patients hospitalized for COPD exacerbation, the presence of atrial fibrillation may increase the risk of in-hospital mortality.